drug · protein

LINZESS

updated 3mo ago

by $ABBV AbbVie Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Protein drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.

targets

Guanylyl cyclase C

all catalysts(0)

nothing on the calendar yet

Trials studying LINZESS

phase2A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotidecompletedn=19
phase3A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipationcompletedn=123
phase3Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)completedn=438
—Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)completedn=2,475
phase3A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipationcompletedn=186
phase2A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndromecompletedn=559
phase3Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndromecompletedn=500

News(0)

no news has mentioned this drug yet

brand

LINZESS

trade names

Constella, Linzess

generic

LINACLOTIDE

MOA

12.1 Mechanism of Action Linaclotide is structurally related to human guanylin and uroguanylin and functions as a guanylate cyclase-C (GC-C) agonist. Both linaclotide and its active metabolite bind to GC-C and act locally on the luminal surface of the intestinal epithelium. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP). Elevation in intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly through activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit. In animal models, linaclotide has been shown to both accelerate GI transit and reduce intestinal pain. In an animal model of visceral pain, linaclotide reduced abdominal muscle contraction and decreased the activity of pain-sensing nerves by increasing extracellular cGMP.

indication

1 INDICATIONS AND USAGE LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older • chronic idiopathic constipation (CIC) in adults • functional constipation (FC) in pediatric patients 6 years of age and older LINZESS is a guanylate cyclase-C agonist indicated for treatment of: Irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older. ( 1 ) Chronic idiopathic constipation (CIC) in adults. ( 1 ) Functional constipation (FC) in pediatric patients 6 years of age and older. ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · protein

save

LINZESS

updated 3mo ago

by $ABBV AbbVie Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Protein drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.

targets

Guanylyl cyclase C

all catalysts(0)

nothing on the calendar yet

Trials studying LINZESS

News(0)

no news has mentioned this drug yet

brand

LINZESS

trade names

Constella, Linzess

generic

LINACLOTIDE

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

LINZESS

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying LINZESS

News(0)

Report a data issue

comments(0)

LINZESS

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying LINZESS

News(0)

Report a data issue

comments(0)